GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Omnicell Inc (STU:OC9) » Definitions » Research & Development

Omnicell (STU:OC9) Research & Development : €89 Mil (TTM As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Omnicell Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Omnicell's Research & Development for the three months ended in Mar. 2024 was €20 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €89 Mil.

Omnicell Research & Development Historical Data

The historical data trend for Omnicell's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omnicell Research & Development Chart

Omnicell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.78 57.67 67.01 99.09 89.05

Omnicell Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.37 21.36 22.75 24.59 20.29

Omnicell Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omnicell  (STU:OC9) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Omnicell Research & Development Related Terms

Thank you for viewing the detailed overview of Omnicell's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Omnicell (STU:OC9) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Omnicell Inc (STU:OC9) » Definitions » Research & Development
Comparable Companies
SDGR PHR BTSG TDOC PINC SLP PRVA HSTM NRC DH GEHC VEEV SOLV ASX:PME HQY TSE:2413 RCM DOCS TXG CERT
Traded in Other Exchanges
OMCL:USA
Address
2625 Augustine Drive, Suite 301, Santa Clara, CA, USA, 95054
Website
https://www.omnicell.com
Omnicell Inc provides automation and business analytics software for healthcare providers. The automation and analytics segment manufactures medication dispensing systems, pharmacy inventory management systems, and related software. The medication adherence segment sells products like consumable medication blister cards and packaging equipment to help administer medication outside of a hospital setting. Omnicell generates the vast majority of its revenue in the United States.

Omnicell (STU:OC9) Headlines

No Headlines